Indaptus Therapeutics, Inc.

As of June 30, 2026, Indaptus Therapeutics, Inc. carries a market capitalization of 399.73M, placing it among publicly traded companies globally. Its enterprise value stands at 388.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Indaptus Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Indaptus Therapeutics, Inc. has 133.24M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Indaptus Therapeutics, Inc. maintains a current ratio of 19.48, meaning it holds 19.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -163.84, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Indaptus Therapeutics, Inc.'s stock has declined approximately 13.33% over the past 52 weeks. The 50-day moving average sits at 2.28, while the 200-day moving average is 2.28.

Over the twelve months ended June 30, 2026, Indaptus Therapeutics, Inc. generated - - in revenue and converted that into -15.42M in net income, yielding earnings per share of -0.47. EBITDA reached -14.77M, while operating income came in at -14.77M.

These figures are as of June 30, 2026. Total book value stands at 11.37M, with working capital of 11.37M providing operational flexibility.

Indaptus Therapeutics, Inc. produced -14.70M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.03, meaning Indaptus Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Indaptus Therapeutics, Inc.'s most recent stock split took place on June 27, 2025 with a 28:1 split ratio.

As of June 30, 2026, Indaptus Therapeutics, Inc. has an Altman Z-Score of 376.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.